Nama's AI scorecard currently rates OPKO Health Sell (3.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does OPK report earnings?

OPKO Health's next scheduled report is on Mar 1, 2027. Analysts expect EPS of -$0.06.

What is the OPK price target?

The median analyst price target from 5 analysts is $3.00, with a range of $2.25 – $8.50.

Is OPK Shariah compliant?

Nama's AAOIFI-style screen reads OPKO Health as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

OPKO Health (OPK)

Healthcare · Diagnostics Research · NASDAQ

OPKO Health (OPK) is a Healthcare company in the Diagnostics Research industry. It has a market capitalization of $1.28B and a free-cash-flow yield of -14.4%. Over the most recent reported fiscal year, revenue declined 14.9%. Nama's AI scorecard rates it Sell, 3.8 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Sell · 3.8/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Lagging · +0.7% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-67.0%

How far the last close sits under the highest price of the past five years.

Market cap	$1.28B
Trailing P/E	—
Price / book	1.1
Price / sales	2.2
FCF yield	-14.4%
Dividend yield	—
Gross margin	40.8%
Operating margin	-28.6%
Net margin	-12.4%
Revenue growth (YoY)	-14.9%
Revenue growth (3-yr annual)	-15.4%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	1.5
Exchange	NASDAQ
Sector	Healthcare
Industry	Diagnostics Research

OPK earnings

Next report: Mar 1, 2027 (Q4 2026, EPS estimate -$0.06). Beat the EPS estimate in 3 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 4, 2026	-$0.05	-$0.06	+16.7%	$65.41M
Q2 2026	Jul 27, 2026	-$0.03	-$0.11	+72.7%	$163.58M
Q1 2026	Apr 28, 2026	-$0.07	-$0.07	+0.0%	$124.20M
Q4 2025	Feb 26, 2026	-$0.04	-$0.07	+42.9%	$148.45M

OPK analyst price target

Median target $3.00 from 5 analysts, ranging $2.25 – $8.50.

Diagnostics Research peers

Ticker	Company	Market cap	P/E
TMO	Thermo Fisher Scientific	$257.42B	28.1
DHR	Danaher	$161.86B	27.6
IDXX	IDEXX Laboratories	$53.26B	45.6
A	Agilent Technologies	$49.28B	28.8
WAT	Waters	$44.93B	31.8
IQV	IQVIA	$44.80B	21.2
NTRA	Natera	$44.78B	—
MTD	Mettler-Toledo International	$34.51B	37.2

Explore live OPK data on Nama Insights →

OPK FAQ

Is OPK a buy?: Nama's AI scorecard currently rates OPKO Health Sell (3.8 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does OPK report earnings?: OPKO Health's next scheduled report is on Mar 1, 2027. Analysts expect EPS of -$0.06.
What is the OPK price target?: The median analyst price target from 5 analysts is $3.00, with a range of $2.25 – $8.50.
Is OPK Shariah compliant?: Nama's AAOIFI-style screen reads OPKO Health as Not Shariah Compliant. At least one of the three ratios or the industry test failed.